Monitoring of Serum DNA Methylation as an Early Independent Marker of Response and Survival in Metastatic Breast Cancer: TBCRC 005 Prospective Biomarker Study
- Visvanathan, Kala
- Fackler, Maryjo S.
- Zhang, Zhe
- Lopez-Bujanda, Zoila A.
- Jeter, Stacie C.
- Sokoll, Lori J.
- Garrett-Mayer, Elizabeth
- Cope, Leslie M.
- Umbricht, Christopher B.
- Euhus, David M.
- Forero, Andres
- Storniolo, Anna M.
- Nanda, Rita
- Lin, Nancy U.
- Carey, Lisa A.
- Ingle, James N.
- Sukumar, Saraswati
- Wolff, Antonio C.
DOIAbstract
Epigenetic alterations measured in blood may help guide breast cancer treatment. The multisite prospective study TBCRC 005 was conducted to examine the ability of a novel panel of cell-free DNA methylation markers to predict survival outcomes in metastatic breast cancer (MBC) using a new quantitative multiplex assay (cMethDNA)
Add to ORKG